Royalty Pharma Quarterly Balance Sheet
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma financial position
As of Jun 30, 2026, Royalty Pharma reported total assets of $19.82 billion, up 8.2% from a year earlier against total liabilities of $10.03 billion. Shareholders' equity stood at $9.79 billion, or 49.4% of assets. The company held $812.0 million in cash and equivalents against $8.96 billion of debt, a net debt position of $8.15 billion.
The current ratio (current assets divided by current liabilities) was 2.80, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.92.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 811.99M | 586.39M | 618.70M | 938.94M | 631.91M | 1.09B | 929.03M | 950.05M | 1.76B | 843.00M | 477.01M | 936.45M |
| Short-Term Investments | 25.00M | 21.90M | 18.80M | 16.10M | 13.20M | 12.10M | 58.20M | 48.50M | 38.50M | 29.00M | 18.30M | 5.30M |
| Total Current Assets | 1.76B | 1.43B | 1.53B | 1.85B | 1.52B | 1.84B | 1.80B | 1.79B | 2.58B | 1.56B | 1.27B | 1.73B |
| Goodwill | 923.53M | 924.63M | 924.63M | 924.63M | 924.63M | — | 0 | — | — | — | — | — |
| Long-Term Investments | 372.10M | 406.80M | 419.00M | 302.50M | 271.90M | 219.00M | 693.50M | 657.30M | 629.90M | 473.70M | 437.10M | 353.60M |
| Total Assets | 19.82B | 19.82B | 19.62B | 19.35B | 18.32B | 17.61B | 18.22B | 18.04B | 17.66B | 16.13B | 16.38B | 15.86B |
| Accounts Payable | 35.57M | 25.48M | 19.40M | 41.41M | 20.21M | 37.63M | 13.37M | 22.05M | 23.42M | 11.55M | 15.16M | 13.63M |
| Short-Term Debt | 380.00M | 380.00M | 380.00M | 380.00M | 999.44M | 998.61M | 997.77M | 996.94M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 630.93M | 535.68M | 636.21M | 530.80M | 1.21B | 1.18B | 1.25B | 1.17B | 275.70M | 124.57M | 161.38M | 127.93M |
| Long-Term Debt | 8.58B | 8.58B | 8.57B | 8.57B | 7.00B | 6.62B | 6.61B | 6.61B | 7.60B | 6.14B | 6.14B | 6.13B |
| Total Liabilities | 10.03B | 9.88B | 9.91B | 9.73B | 8.82B | 7.82B | 7.88B | 7.78B | 7.90B | 6.27B | 6.30B | 6.27B |
| Shareholders' Equity | 9.79B | 9.94B | 9.71B | 9.62B | 9.49B | 9.78B | 10.34B | 10.26B | 9.75B | 9.86B | 10.08B | 9.59B |
| Retained Earnings | 2.46B | 2.51B | 2.36B | 2.30B | 2.22B | 2.48B | 2.85B | 2.76B | 2.38B | 2.43B | 2.52B | 2.13B |
| Total Debt | 8.96B | 8.96B | 8.95B | 8.95B | 8.00B | 7.62B | 7.61B | 7.61B | 7.60B | 6.14B | 6.14B | 6.13B |
| Net Cash (Debt) | -8.12B | -8.35B | -8.31B | -7.99B | -7.36B | -6.52B | -6.63B | -6.61B | -5.80B | -5.27B | -5.64B | -5.19B |
This table shows 12 quarterly periods of Royalty Pharma's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RPRX's reporting calendar. What is a balance sheet?